ArticleInfluenza and other respiratory viruses2024
Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review.Human vaccines & immunotherapeutics · 2026Review
- Observational
- Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study.Children (Basel, Switzerland) · 2026Article
- Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis.PLoS medicine · 2026Article
- From Confidence to Coverage: A Multi-Stakeholder Perspective on Vaccination in Central and Eastern Europe.Vaccines · 2026Article
- Coverage, Timing, Safety, and Determinants of Neonatal Intensive Care Unit Admission in Newborns Receiving Nirsevimab Prophylaxis for Respiratory Syncytial Virus.Pathogens (Basel, Switzerland) · 2026Observational
- Health care utilization and cost implications of Chile's 2024 nirsevimab strategy for RSV prevention: a counterfactual analysis.Lancet regional health. Americas · 2026Article
- Impact of regional heterogeneity of RSV infection prophylaxis on bronchiolitis in Italy.Italian journal of pediatrics · 2026Observational
- Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants.Pediatric pulmonology · 2026Article
- Incidence of Respiratory Syncytial Virus Infection Among Patients Aged Less Than 2 Years: A Retrospective Study From an Italian Southern Region in Years 2018-2023.Influenza and other respiratory viruses · 2026Observational
- Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.JAMA network open · 2026Article
- Real-world effectiveness of nirsevimab against RSV hospitalisation in infants during a season with low coverage and delayed circulation in Beijing, China: a population-based retrospective cohort study.The Lancet regional health. Western Pacific · 2026Article
- Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study.Italian journal of pediatrics · 2026Observational
- Article
- Reduction in Respiratory Syncytial Virus (RSV)-Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany.Influenza and other respiratory viruses · 2026Article
- Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.